A
weekly e-journal by Art Epstein, OD, FAAO
Volume 10, Number 27 |
Monday, July 12, 2010 |
A few years ago, I was headed back to NYC from the AOA Spring Planning meeting in
St. Louis. Rather than go home, I was going to catch a plane to Ft. Lauderdale for ARVO and an
editorial board meeting the next morning.
|
|||||||
Diplopia Following Cataract Extraction and Refractive Surgery | ||||
The purpose of this article is to report the incidence and cause of diplopia following cataract
surgery and laser in-situ keratomileusis (LASIK).
Ocular misalignment following cataract extraction with retrobulbar anesthesia has an incidence of approximately 7%. Diplopia ranges in this group of patients from 0.23 to 0.98%.The incidence of ocular misalignment decreases with topical anesthesia for cataract extraction to 5%, and diplopia occurs with an incidence of 0.21-0%. Although there are small case series, the incidence of diplopia following LASIK has not been reported. The causes of diplopia following cataract extraction and LASIK include decompensation of pre-existing strabismus, new-onset accommodative esotropia, concurrent onset of systemic disease, disruption of central fusion, and monocular diplopia. The leading cause for diplopia following retrobulbar anesthesia for cataract extraction is extraocular muscle paresis/restriction and is unique to this type of procedure. In cases of topical anesthesia for cataract extraction and for LASIK procedures, the leading cause of diplopia is decompensation of pre-existing strabismus. Detailed history and evaluation for pre-existing strabismus can dramatically decrease the incidence of unexpected diplopia following refractive procedures. |
||||
SOURCE: Gunton KB, Armstrong B. Diplopia in adult patients following cataract extraction and refractive surgery. Curr Opin Ophthalmol 2010;Jul 1 [Epub ahead of print]. |
Efficacy and Safety of Lucentis for Naïve Retinal Vein Occlusion | ||||
Seventeen eyes of 17 consecutive patients with naïve retinal vein occlusion
were evaluated for the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients
with treatment-naïve retinal vein occlusion. Consecutive patients were recruited and received,
on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and
eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included
measurement of best corrected visual acuity (BCVA) for distance and near vision (MNREAD time,
reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and
optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months. Main
outcome measures were change in BCVA, contrast sensitivity, angiographic leakage, OCT central
macular thickness (CMT), number of treatments.
Patients with CRVO had mean pre-treatment BCVA of 20/240 and final BCVA of 20/46, with significant improvement at 1 year of follow up. At 12 months, mean BCVA improved to 36.7 letters, with a gain of 6.4 lines and OCT showed that the mean CMT was 271 µm, with a mean reduction of 360 µm from baseline. Patients with BRVO had mean pre-treatment BCVA of 20/126 and final BCVA of 20/50. The mean OCT CMT was 278 µm, with a mean reduction of 275 µm from baseline. Contrast sensitivity, MNREAD time and reading fluency improved significantly in the treated eyes. No ocular or systemic side effects were observed. Eyes with CRVO received an average of 3.0 injections (range 2-4) and those with BRVO 3.6 (range 3-4). Intravitreal ranibizumab for the management of naive CRVO or BRVO can favorably modify the course of the occlusion, indicating that short- and long-term blockade of vascular endothelial growth factor (VEGF)-A may restore the integrity of the inner blood-retinal barrier, reduce CMT and significantly improve visual function, with a good safety profile. Further prospective long-term studies are warranted to confirm the efficacy, safety and optimal treatment regimen for intravitreal ranibizumab. |
||||
SOURCE: Pece A, Isola V, Piermarocchi S, Calori G. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2010;Jul 3 [Epub ahead of print]. |
Contact Lens Deposits, Adverse Responses and Clinical Ocular Surface Parameters | ||||
Clinical parameters, including adverse response rates and corneal staining, and
symptomatology rating during lens wear were collected from a series of clinical tests comprising four
different silicone hydrogel lenses with four different multipurpose solutions to correlate clinical
responses during contact lens wear with the amount of protein or cholesterol extracted from lenses after
wear. To test for correlates, the amount of total protein or cholesterol extracted from lenses after
daily wear were compared statistically to clinical parameters.
The amount of protein or cholesterol extracted from lenses was higher for those subjects who showed solution-induced corneal staining. Amount of protein extracted was correlated with conjunctival staining, lens front surface wetting and lens fit tightness. These clinical parameters accounted for 48% of lens protein deposition. The amount of cholesterol extracted from lenses was much more weakly associated with clinical variables. Amount of protein or cholesterol extracted from lenses was not associated with the production of any corneal infiltrative or mechanical adverse event during wear and was only very weakly correlated with insertion comfort of lenses. These results suggest that there may be no physiologically relevant consequence of cholesterol depositing on silicone hydrogel lenses. The amount of protein that deposits onto silicone hydrogel lenses during wear may have more affect on lens performance on-eye. However, the correlations were generally small and may still not indicate any causative relevant physiological response. Further work is required to determine whether there is any direct causative effect to support these correlative findings. |
||||
SOURCE: Zhao Z, Naduvilath T, Flanagan JL, et al. Contact lens deposits, adverse responses, and clinical ocular surface parameters. Optom Vis Sci 2010;Jul 1 [Epub ahead of print]. |
News & Notes | ||
ALCON LITIGATION TRUST CREATED. The Alcon Independent Director Committee (IDC) recently reported the creation and funding of the Alcon Litigation Trust, an irrevocable trust established under New York law pursuant to a resolution of the Alcon board of directors. The initial trustees of the Trust consist of the current members of the IDC. The Trust, which has been funded with $50 million, is intended to provide the financial means to commence, defend or maintain litigation relating to any transaction between Alcon and a majority shareholder. According to Alcon, the Trust has been created to ensure the protection of the interests of Alcon and its minority shareholders in connection with any such transaction. Learn more here. Additionally, the IDC has posted the complete trust agreement, which includes all terms and conditions governing the Trust, on its website. | ||
ACCORD EYE STUDY REVEALS TWO PROMISING THERAPIES FOR SLOWING DIABETIC EYE DISEASE PROGRESSION. Researchers for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study have found that in high-risk adults with type 2 diabetes, two therapies may slow the progression of diabetic retinopathy. Intensive blood sugar control reduced the progression of diabetic retinopathy compared with standard blood sugar control and combination lipid therapy with a fibrate and statin also reduced disease progression compared with statin therapy alone, whereas intensive blood pressure control provided no additional benefit to patients compared with standard blood pressure control. Find more information about this trial (NCT00542178) at www.clinicaltrials.gov or read the published results of the ACCORD Eye Study. | ||
OCUSOFT REDESIGNS WEBSITE FOR RX DRY EYE SUPPLEMENT. OCuSOFT, Inc. has launched a newly redesigned website for its prescription-only supplement for dry eye, Tears Again Hydrate. The company says the website has been updated with a new look and improved navigation to increase functionality and overall user friendliness. | ||
RENU MULTIPURPOSE SOLUTION AND RENU MULTIPLUS MULTI-PURPOSE SOLUTION VOLUNTARILY RECALLED IN EUROPE AND MIDDLE EAST. In a statement to the media, Bausch + Lomb announced that it is conducting a voluntary recall of a limited number of lots of its ReNu Multi-Purpose Solution and ReNu MultiPlus multi-purpose solution in Europe and the Middle East. A small number of sensitivity issues with a single lot (AA120) of 120ML ReNu MultiPlus multi-purpose solution in Croatia, Dubai, Hungary, Serbia, Romania, Turkey and Saudi Arabia have been reported; therefore, Bausch + Lomb has made the decision to initiate a voluntary recall of this product. In a separate action, routine testing has shown that although ReNu Multi-Purpose Solution and ReNu MultiPlus multi-purpose solution are safe and effective when used as directed, they are not meeting Bausch + Lomb's quality expectations; therefore, the company is also voluntarily recalling a limited number of lots of these products in Europe. It has notified retailers and eyecare professionals about the steps they should take if they have a product from the affected lots. | ||
|
HOW TO SUBMIT NEWS
HOW TO ADVERTISE
|